<DOC>
	<DOC>NCT02161653</DOC>
	<brief_summary>The purpose of this study is to determine whether metadoxine is effective for improve survival and reduced oxidative stress in patients with severe alcoholic hepatitis.</brief_summary>
	<brief_title>Metadoxine as a Therapy for Severe Alcoholic Hepatitis</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis, Alcoholic</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Pentoxifylline</mesh_term>
	<mesh_term>Metadoxine</mesh_term>
	<mesh_term>Pyridoxine</mesh_term>
	<criteria>Patients with clinical and biochemical criteria for severe alcoholic hepatitis: Total bilirubin greater than 5 mg/dl in absence of biliary tract obstruction evidenced by ultrasound, history of chronic alcohol intake, leukocytosis, neutrophilia, elevation of transaminases with an aspartate aminotransferase / alanine aminotransferase ratio equal or greater than 2, discriminant function greater than 32. Diabetes, chronic kidney disease, hepatitis C, hepatitis B and or human immunodeficiency virus infection, asthma or history of atopy or allergic reactions, therapy in the previous two years with steroids, pentoxifylline, metadoxine, Sadenosyl L methionine, antioxidants or multivitamins.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Severe alcoholic hepatitis</keyword>
	<keyword>survival</keyword>
	<keyword>oxidative stress</keyword>
</DOC>